Cancer immunotherapy based on blocking immune suppression mediated by an immune modulator LAIR-1

References

• Vivier E, Daëron M. Immunoreceptor tyrosine-based inhibition motifs. Immunol Today. 1997;18(6):286–9. doi:10.1016/S0167-5699(97)80025-4.
   PubMedGoogle Scholar
• Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity. 1997;7(2):283–290. doi:10.1016/S1074-7613(00)80530-0.
   PubMed Web of Science ®Google Scholar
• Poggi A, Pella N, Morelli L, Spada F, Revello V, Sivori S, Augugliaro R, Moretta L, Moretta A. p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans. Eur J Immunol. 1995;25(2):369–376. doi:10.1002/()1521-4141.
   PubMed Web of Science ®Google Scholar
• Verbrugge A, de Ruiter T, Geest C, Coffer PJ, Meyaard L. Differential expression of leukocyte-associated Ig-like receptor-1 during neutrophil differentiation and activation. J Leukoc Biol. 2006;79(4):828–836. doi:10.1189/jlb.0705370.
   PubMed Web of Science ®Google Scholar
• Poggi A, Tomasello E, Ferrero E, Zocchi MR, Moretta L. p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulating factor. Eur J Immunol. 1998;28(7):2086–2091. doi:10.1002/()1521-4141.
   PubMed Web of Science ®Google Scholar
• Florian S, Sonneck K, Czerny M, Hennersdorf F, Hauswirth AW, Buhring H-J, Valent P. Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy. 2006;61(9):1054–1062. doi:10.1111/all.2006.61.issue-9.
   PubMed Web of Science ®Google Scholar
• Daeron M, Jaeger S, Du Pasquier L, Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev. 2008;224(1):11–43. doi:10.1111/imr.2008.224.issue-1.
   PubMedGoogle Scholar
• Meyaard L, Hurenkamp J, Clevers H, Lanier LL, Phillips JH. Leukocyte-associated Ig-like receptor-1 functions as an inhibitory receptor on cytotoxic T cells. J Immunol. 1999;162:5800–5804.
   PubMed Web of Science ®Google Scholar
• Maasho K, Masilamani M, Valas R, Basu S, Coligan J, Borrego F. The inhibitory leukocyte-associated Ig-like receptor-1 (LAIR-1) is expressed at high levels by human naive T cells and inhibits TCR mediated activation. Mol Immunol. 2005;42(12):1521–1530. doi:10.1016/j.molimm.2005.01.004.
   PubMed Web of Science ®Google Scholar
• Tomasello E, Revello V, Nanni L, Costa P, Moretta L, Poggi A, p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes. Int Immunol. 1997;9(9):1271–1279. doi:10.1093/intimm/9.9.1271.
   PubMed Web of Science ®Google Scholar
• Jansen CA, Cruijsen C, de Ruiter T, Nanlohy N, Willems N, Janssens-Korpela P-L, Meyaard L. Regulated expression of the inhibitory receptor LAIR-1 on human peripheral T cells during T cell activation and differentiation. Eur J Immunol. 2007;37(4):914–924. doi:10.1002/()1521-4141.
   PubMed Web of Science ®Google Scholar
• Saverino D, Fabbi M, Merlo A, Ravera G, Grossi CE, Ciccone E. Surface density expression of the leukocyte-associated Ig-like receptor-1 is directly related to inhibition of human T-cell functions. Hum Immunol. 2002;63(7):534–546. doi:10.1016/S0198-8859(02)00409-3.
   PubMed Web of Science ®Google Scholar
• Lebbink RJ, de Ruiter T, Kaptijn GJA, Bihan DG, Jansen CA, Lenting PJ, Meyaard L. Mouse leukocyte-associated Ig-like receptor-1 (mLAIR-1) functions as an inhibitory collagen-binding receptor on immune cells. Int Immunol. 2007;19(8):1011–1019. doi:10.1093/intimm/dxm071.
   PubMed Web of Science ®Google Scholar
• Lebbink RJ, de Ruiter T, Adelmeijer J, Brenkman AB, van Helvoort JM, Koch M, Farndale RW, Lisman T, Sonnenberg A, Lenting PJ, et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med. 2006;203(6):1419–1425. doi:10.1084/jem.20052554.
   PubMed Web of Science ®Google Scholar
• Huijbers IJ, Iravani M, Popov S, Robertson D, Al-Sarraj S, Jones C, Isacke CM. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS One. 2010;5(3):e9808. doi:10.1371/journal.pone.0009808.
   PubMed Web of Science ®Google Scholar
• Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 2010;22(5):697–706. doi:10.1016/j.ceb.2010.08.015.
   PubMed Web of Science ®Google Scholar
• Meyaard L. LAIR and collagens in immune regulation. Immunol Lett. 2010;128(1):26–28. doi:10.1016/j.imlet.2009.09.014.
   PubMed Web of Science ®Google Scholar
• Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol. 2008;83(4):799–803. doi:10.1189/jlb.0907609.
   PubMed Web of Science ®Google Scholar
• Jingushi K, Uemura M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, Yamamoto Y, Hayashi T, Kinouchi T, Matsuzaki K, et al. Leukocyteassociated immunoglobulinlike receptor 1 promotes tumorigenesis in RCC. Oncol Rep. 2019;41(2):1293–1303. doi:10.3892/or.2018.6875.
   PubMed Web of Science ®Google Scholar
• Lebbink RJ, van den Berg MCW, de Ruiter T, Raynal N, van Roon JAG, Lenting PJ, Jin B, Meyaard L. The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction. J Immunol. 2008;180(3):1662–1669. doi:10.4049/jimmunol.180.3.1662.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002.
   PubMed Web of Science ®Google Scholar
• Li B, Xu L, Pi C, Yin Y, Xie K, Tao F, Li R, Gu H, Fang J. CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy. Oncoimmunology. 2017;7(1):e1380142. doi:10.1080/2162402X.2017.1380142.
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011;3(5):422–430. doi:10.4161/mabs.3.5.16983.
   PubMed Web of Science ®Google Scholar
• Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, Han X, Xie F, Tyner JW, Coligan JE, et al. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nat Cell Biol. 2015;17(5):665–677. doi:10.1038/ncb3158.
   PubMed Web of Science ®Google Scholar
• Rygiel TP, Stolte EH, de Ruiter T, van de Weijer ML, Meyaard L. Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1. Mol Immunol. 2011;49(1–2):402–406. doi:10.1016/j.molimm.2011.09.006.
   PubMed Web of Science ®Google Scholar
• Lebbink RJ, de Ruiter T, Verbrugge A, Bril WS, Meyaard L. The mouse homologue of the leukocyte-associated Ig-like receptor-1 is an inhibitory receptor that recruits Src homology region 2-containing protein tyrosine phosphatase (SHP)-2, but not SHP-1. J Immunol. 2004;172(9):5535–5543. doi:10.4049/jimmunol.172.9.5535.
   PubMed Web of Science ®Google Scholar
• Lebbink RJ, de Ruiter T, Kaptijn GJ, Meyaard L. Identification and characterization of the rat homologue of LAIR-1. Immunogenetics. 2005;57(5):344–351. doi:10.1007/s00251-005-0804-4.
   PubMed Web of Science ®Google Scholar
• Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. 1999;72:149–177.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25(4):656–666. doi:10.1038/s41591-019-0374-x.
   PubMed Web of Science ®Google Scholar
• Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19(1):76–84. doi:10.1038/s41590-017-0004-z.
   PubMed Web of Science ®Google Scholar
• Cao Q, Fu A, Yang S, He X, Wang Y, Zhang X, Zhou J, Luan X, Yu W, Xue J. Leukocyte-associated immunoglobulin-like receptor-1 expressed in epithelial ovarian cancer cells and involved in cell proliferation and invasion. Biochem Biophys Res Commun. 2015;458(2):399‑404. doi:10.1016/j.bbrc.2015.01.127.
   Web of Science ®Google Scholar
• Kumawat K, Geerdink RJ, Hennus MP, Roda MA, van Ark I, Leusink-Muis T, Folkerts G, van Oort-jansen A, Mazharian A, Watson SP, et al. LAIR-1 limits neutrophilic airway inflammation. Front Immunol. 2019;10:842. doi:10.3389/fimmu.2019.00842.
   PubMed Web of Science ®Google Scholar
• Jiang W, Kim YS, Zhang CC, Fu YX, Weissman IL.Feng M. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19(8):568–586.
   PubMedGoogle Scholar
• Barclay AN, van den Berg TK. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32(1):25–50. doi:10.1146/annurev-immunol-032713-120142.
   PubMedGoogle Scholar